Medplus Health

Why is Medplus Health Services Ltd falling/rising?

As of 08-Jul, Medplus Health Services Ltd's stock price is declining, currently at Rs 812.70, with a total drop of -1.11% over the last three days. Despite positive long-term growth indicators, the stock is trading below key moving averages and experiencing reduced investor interest.

As of 08-Jul, Medplus Health Services Ltd is experiencing a decline in its stock price, currently at Rs 812.70, which reflects a change of -4.15 (-0.51%). The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -1.11% during this period. Additionally, the stock has touched an intraday low of Rs 800.05, marking a decrease of -2.06%.<BR><BR>The stock's performance over the past week shows a slight decline of -0.36%, which is slightly better than the benchmark Sensex's drop of -0.54%. However, over the past month, Medplus has seen a more significant decline of -4.75%, contrasting sharply with the Sensex's increase of +4.05%. Year-to-date, the stock has managed a modest gain of +0.81%, while the Sensex has fallen by -10.23%. <BR><BR>Despite some positive long-term growth indicators, such as a 20.68% annual growth rate in operating profit and a 25.26% increase in profit after tax over the last six months, the stock is currently trading below its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day). This suggests a bearish trend in the short term. Furthermore, investor participation appears to be declining, with delivery volume dropping by -78.64% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>Overall, while Medplus Health Services Ltd has shown healthy long-term growth metrics, the current stock price decline is attributed to recent negative performance trends, lower investor participation, and trading below key moving averages.

Which are the latest news on Medplus Health?

When is the next results date for Medplus Health Services Ltd?

The next results date for Medplus Health Services Ltd is 21 July 2026.

The next results date for Medplus Health Services Ltd is scheduled for 21 July 2026.

Should I buy, sell or hold Medplus Health Services Ltd?

What does Medplus Health do?

MedPlus Health Services Limited is a small-cap retail company specializing in health services, incorporated in 2006 and transitioned to a public company in 2021. As of March 2026, it reported net sales of ₹1,864 Cr and a net profit of ₹64 Cr, with a market cap of ₹10,388 Cr.

Overview:<BR>MedPlus Health Services Limited operates in the retailing industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 2006 as 'MedPlus Health Services Private Limited' in Hyderabad. It transitioned from a Private Limited Company to a Public Limited Company on 1 June 2021, and its name was changed to MedPlus Health Services Limited on 28 June 2021. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,864 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 64 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 10,388 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 47.00 <BR>Industry P/E: 72 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.49 <BR>Return on Equity: 11.12% <BR>Price to Book: 5.24 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Medplus Health?

As of 10th June, Medplus Health Services Ltd has a market capitalization of 10,388.00 Cr and reported net sales of 6,892.47 Cr and a net profit of 219.65 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Medplus Health Services Ltd has a market capitalization of 10,388.00 Cr, classifying it as a Small Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 6,892.47 Cr, while the sum of Net Profit for the same period is 219.65 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,740.56 Cr, and Total Assets amount to 3,260.27 Cr.

Who are in the management team of Medplus Health?

The management team of Medplus Health includes GANGADI MADHUKAR REDDY (Chairman, Managing Director, and CEO), Anish Saraf (Director), Atul Gupta (Nominee), and three Independent Directors: Murali Sivaraman, Madhavan Ganesan, and Hiroo Mirchandani, along with Manoj Kumar Srivastava (Company Secretary and Compliance Officer).

The management team of Medplus Health includes the following key individuals:<BR><BR>1. **GANGADI MADHUKAR REDDY** - Chairman, Managing Director, and CEO<BR>2. **Anish Saraf** - Director<BR>3. **Atul Gupta** - Nominee<BR>4. **Murali Sivaraman** - Independent Director<BR>5. **Madhavan Ganesan** - Independent Director<BR>6. **Hiroo Mirchandani** - Independent Director<BR>7. **Manoj Kumar Srivastava** - Company Secretary and Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Medplus Health?

Medplus Health's peers include A B Lifestyle, Aditya Vision, Entero Healthcare, Khemani Distribution, M K Exim India, Novelix Pharma, Purple United, Silgo Retail, and Magson Retail. Notably, Medplus Health has a 1-year return of -2.37%, with peers like Novelix Pharma showing a return of 153.02% and M K Exim India at -25.20%.

Peers: The peers of Medplus Health are A B Lifestyle, Aditya Vision, Entero Healthcar, Khemani Distrib., M K Exim India, Novelix Pharma., Purple United, Silgo Retail, and Magson Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aditya Vision, Entero Healthcar, Khemani Distrib., and Purple United, while Good management risk is found at M K Exim India and the rest. Growth is excellent at Medplus Health, Aditya Vision, Entero Healthcar, and Purple United, while Good growth is noted at Novelix Pharma. Below Average growth is seen at A B Lifestyle, Khemani Distrib., M K Exim India, Silgo Retail, and Magson Retail. Capital Structure is excellent at M K Exim India, good at Entero Healthcar, Khemani Distrib., and the rest, while below average is noted at Medplus Health, A B Lifestyle, Novelix Pharma, Silgo Retail, and Magson Retail.<BR><BR>Return Snapshot: Novelix Pharma. has the highest 1-year return at 153.02%, while M K Exim India has the lowest at -25.20%. Medplus Health's 1-year return is -2.37%, which is better than M K Exim India but worse than Novelix Pharma. Additionally, Khemani Distrib., M K Exim India, and Magson Retail have negative six-month returns.

Are Medplus Health Services Ltd latest results good or bad?

MedPlus Health Services Ltd's latest Q4 FY26 results are positive, with a net profit of ₹63.98 crore (up 24.62% year-on-year) and revenue growth of 23.50% to ₹1,864.39 crore. The company also improved its operating margin to 9.07%, indicating strong performance and effective cost management in the competitive pharmacy retail sector.

MedPlus Health Services Ltd's latest results for Q4 FY26 are quite positive. The company reported a net profit of ₹63.98 crore, which represents a significant year-on-year increase of 24.62%. Additionally, revenue grew by 23.50% year-on-year, reaching ₹1,864.39 crore, indicating strong sales momentum.<BR><BR>One of the standout features of this quarter's performance is the operating margin, which improved to 9.07%, the highest level in eight quarters. This reflects effective cost management and operational efficiency, which are crucial in the low-margin pharmacy retail sector. The PAT margin also saw a slight increase to 3.43%, showing the company's ability to convert revenue growth into profit effectively.<BR><BR>Overall, MedPlus appears to be on a solid growth trajectory, with institutional investors showing confidence in the company, as evidenced by a 43.35% holding rate. The results indicate that MedPlus is successfully navigating the competitive landscape of organized pharmacy retail, making the latest performance results favorable.

How has been the historical performance of Medplus Health?

Medplus Health has shown consistent growth in net sales and profitability, with net sales increasing from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025, and profit after tax rising from INR 1.79 crore to INR 150.23 crore during the same period. The company's total assets and cash flow from operating activities have also significantly improved.

Answer:<BR>The historical performance of Medplus Health shows a consistent growth trajectory in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Medplus Health's net sales have steadily increased from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 2,870.60 crore to INR 6,136.05 crore during the same period. The company's total expenditure, excluding depreciation, also grew, reaching INR 5,648.95 crore in March 2025, up from INR 2,736.92 crore in March 2020. Operating profit (PBDIT) has shown a significant increase, rising from INR 150.96 crore in March 2020 to INR 535.72 crore in March 2025. The profit before tax has also improved, moving from INR 29.36 crore in March 2020 to INR 183.29 crore in March 2025, while profit after tax increased from INR 1.79 crore to INR 150.23 crore in the same timeframe. The company's total assets have grown from INR 1,308.54 crore in March 2020 to INR 3,260.27 crore in March 2025, and total liabilities have increased from INR 1,308.54 crore to INR 3,260.27 crore. Cash flow from operating activities has improved significantly, reaching INR 540 crore in March 2025, compared to INR -6 crore in March 2020. Overall, Medplus Health has demonstrated robust growth in sales, profits, and asset base over the years.

Is Medplus Health technically bullish or bearish?

As of November 24, 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD and KST, mixed Bollinger Bands, and no momentum from the RSI, suggesting a cautious approach as the stock remains below its 52-week high.

As of 24 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages also reflect a mildly bearish outlook. The Bollinger Bands show a mixed signal with a mildly bearish stance on the weekly and bullish on the monthly. The Dow Theory indicates no trend on the weekly and mildly bearish on the monthly, contributing to the overall bearish sentiment. The RSI shows no signals in both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its 52-week high.

Is Medplus Health overvalued or undervalued?

As of November 3, 2025, Medplus Health is considered attractive but overvalued due to a high PE ratio of 49.98 and low profitability metrics, despite a strong recent stock performance.

As of 3 November 2025, the valuation grade for Medplus Health has moved from very attractive to attractive. The company is currently considered overvalued based on its high PE ratio of 49.98 and an EV to EBITDA ratio of 13.80, which are significantly higher than its peers. For instance, Avenue Supermarts and Trent have PE ratios of 98.98 and 105.78, respectively, indicating that Medplus Health, while attractive, is still trading at a premium compared to its competitors.<BR><BR>In terms of key financial metrics, Medplus Health has a Price to Book Value of 0.53 and a PEG Ratio of 0.53, suggesting some growth potential relative to its price. However, the low ROCE of 1.77% and ROE of 1.06% raise concerns about profitability and efficiency. Despite a recent strong performance with a 1-year stock return of 19.68% compared to the Sensex's 5.34%, the overall valuation suggests that Medplus Health may be overvalued in the current market environment.

Who are the top shareholders of the Medplus Health?

The top shareholders of Medplus Health include promoters with 59.34% pledged holdings, led by Lone Furrow Investments Private Limited at 14.44%. Mutual funds hold 21.59%, foreign institutional investors 15.61%, and individual investors account for 13.1%.

The top shareholders of Medplus Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with a significant portion of their holdings pledged at 59.34%. <BR><BR>The promoter with the highest holding is Lone Furrow Investments Private Limited, which owns 14.44% of the company. Mutual funds collectively hold 21.59% of the shares through 17 different schemes, while FIIs hold 15.61% through 147 different investors. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 7.58%. Additionally, individual investors account for 13.1% of the total shareholding.

Has Medplus Health declared dividend?

No Dividend History Available